

bluebird bio, Inc.
Form 8-K
January 09, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 9, 2017

bluebird bio, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE

001-35966

13-3680878

(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation) Identification No.)

150 Second Street

Cambridge, MA

02141

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (339) 499-9300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: bluebird bio, Inc. - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

The Company intends to share with investors the amount of cash, cash equivalents and marketable securities it had on hand as of December 31, 2016. Although the Company has not finalized its financial results for the twelve months ended December 31, 2016, the Company currently anticipates that its cash, cash equivalents and marketable securities were approximately \$885 million as of December 31, 2016. This information is unaudited and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2016 and its results of operations for the twelve months ended December 31, 2016. The Company expects to announce its full results for the twelve months ended December 31, 2016 on or before March 1, 2017.

Item 7.01 Regulation FD Disclosure.

The Company will be conducting meetings with investors attending the 35th Annual J.P. Morgan Healthcare Conference in San Francisco beginning on January 9, 2017. As part of these meetings, the Company will deliver the slide presentation furnished to this report as Exhibit 99.1 and which is incorporated herein by reference.

See Item 2.02 above, which is incorporated by reference herein.

The information in this report furnished pursuant to Items 2.02 and 7.01 shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Items 2.02 and 7.01 of this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Investor presentation furnished by bluebird bio, Inc. on January 9, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 9, 2017 bluebird bio,
Inc.

By: /s/
Jason
F. Cole
Jason
F. Cole
Chief
Legal
Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Investor presentation furnished by bluebird bio, Inc. on January 9, 2017.